BMX and in situ carcinoma: The percentage of positive BMX staining was significantly increased from 26.47% (NC samples, 9/34) to 68.00% (CIS samples, 17/25) and 88.46% (ICC samples, 46/52, Figure 1B), and the immunoreactivity score (IRS) of BMX staining was also increased from 2.441 ± 2.286 (NC samples) to 5.280 ± 4.326 (CIS samples) and 5.981 ± 2.920 (ICC samples) (Figure 1C), indicating that BMX may be increased during the progression of human cervical carcinoma.